For example, 1 is reported to exhibit inhibitory activity towards both acetylcholinesterase (AChE) and β-secretase (BACE-1), which suggests that 1 could hold promise as a dual mechanism-of-action treatment for Alzheimer’s disease [4,10–13]. Here, BACE1 is linked to early-onset autosomal dominant Alzheimer disease.